UBS analyst Manav Gupta raised the firm’s price target on Calumet (CLMT) to $13.25 from $12 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet Specialty Products’ Strong Quarter Amidst Challenges
- Calumet Specialty Products: Strategic Positioning and Operational Improvements Drive Buy Rating
- Calumet Specialty Products: Hold Rating Amid Strategic Positioning and Future Debt Challenges
- Calumet Specialty Products Reports Q2 2025 Results
- Calumet reports Q2 EPS ($1.70) vs. (48c) last year